‘Significant progress’ for life sciences business Optibiotix

Two research scientists looking at microscope slides

‘Significant progress’ for life sciences business Optibiotix

Optibiotix says it has made “significant progress” developing a pipeline of innovative products in the first half of the year as it evolves from a technology company to a product firm, following the flotation of its skincare-focused subsidiary and investment in a weight loss business.

Stephen O’Hara, CEO of OptiBiotix, said: “OptiBiotix has made significant progress in the last six months developing a pipeline of innovative products with a strong scientific and clinical evidence base.”

See the article in full at TheBusinessDesk.com

Important information

This information is of a general nature and does not constitute an offer to provide services.

The opinions and conclusions given here are those of Seneca Partners and are subject to change without notice.

The value of investments and/or any income arising from them may fluctuate.

Past performance is not necessarily a guide to future performance.

Important notice

The products and services shown on this website place capital at risk. Investors may receive less in returns than they have invested. Investments may not allow for capital to be withdrawn on demand. If an investment provides tax relief then this relief is subject to change and is dependant on personal circumstances. Any reference to past performance or forecasted performance is not a reliable indicator of future performance.

Seneca Partners recommends that any investor seeks specialised financial and/or tax advice before investing. Seneca Partners does not provide advice and the information on this website, including but not limited to news, should not be construed as such.

Please confirm that you understand this warning and wish to proceed.